BioCentury | Oct 26, 2018
Product Development

R&D merry-go-round

...brought entrepreneurial experience as co-founder of Acetylon Pharmaceuticals Inc., C4 Therapeutics Inc., Syros Pharmaceuticals Inc., Tensha Therapeutics Inc....
BioCentury | Jun 30, 2016
Strategy

Open house at NIBR

...He also co-founded Acetylon Pharmaceuticals Inc. , C4 Therapeutics Inc. , Syros Pharmaceuticals Inc. , Tensha Therapeutics Inc....
BioCentury | Jan 18, 2016
Company News

Tensha Therapeutics, Roche deal

...acquisition is expected to close this quarter. The companies declined to provide further financial terms. Tensha Therapeutics Inc....
BioCentury | Jan 12, 2016
Company News

Roche BETs on Tensha

...Roche (SIX:ROG; OTCQX:RHHBY) will acquire Tensha Therapeutics Inc. (Cambridge, Mass.) for $115 million in cash up front. Tensha...
BioCentury | Jan 5, 2015
Product Development

BETting early

...2013, the pharma said it expects to report data in late 2014 or early 2015. Tensha Therapeutics Inc....
...Md. Oncoethix S.A., Lausanne, Switzerland Resverlogix Corp. (TSX:RVX), Calgary, Alberta Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Tensha Therapeutics Inc....
BioCentury | Oct 30, 2014
Cover Story

Redistributing BRD4 in inflammation

...investigator in the Department of Medical Oncology at the Dana-Farber Cancer Institute and founder of Tensha Therapeutics Inc....
...Boston, Mass. Resverlogix Corp. (TSX:RVX), Calgary, Alberta, Canada Syros Pharmaceuticals Inc. , Watertown, Mass. Tensha Therapeutics Inc....
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Various

...of BRD4 and other BET bromodomain proteins, has completed Phase II trials to treat atherosclerosis. Tensha Therapeutics Inc....
...Patent application covering JQ1 and related analogs filed by the Dana-Farber Cancer Institute; licensed to Tensha Therapeutics...
BioCentury | Jul 31, 2014
Targets & Mechanisms

Taking a BET on hedgehog

...has filed a patent application covering JQ1 and related analogs. The technology is licensed to Tensha Therapeutics Inc....
...Arbor, Mich. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Stanford University School Of Medicine , Stanford, Calif. Tensha Therapeutics Inc....
BioCentury | Jul 24, 2014
Distillery Therapeutics

Indication: Cancer

...companies have BET bromodomain inhibitors in Phase I testing or preclinical development for various cancers. Tensha Therapeutics Inc....
...2014 Patent application covering JQ1 and related analogs filed by Dana-Farber Cancer Institute; licensed to Tensha Therapeutics...
BioCentury | May 15, 2014
Cover Story

Chromatin's rising tide

...the clinic ( see Table 1). These include TEN-010 , a compound being developed by Tensha Therapeutics Inc....
...NYSE:SNY), Paris, France Structural Genomics Consortium , Oxford, U.K. Syros Pharmaceuticals Inc. , Watertown, Mass. Tensha Therapeutics Inc....
...Oncoethix S.A.; Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) OTX015 BET bromodomain inhibitor Hematologic malignancies Phase I Tensha Therapeutics Inc....
Items per page:
1 - 10 of 33
BioCentury | Oct 26, 2018
Product Development

R&D merry-go-round

...brought entrepreneurial experience as co-founder of Acetylon Pharmaceuticals Inc., C4 Therapeutics Inc., Syros Pharmaceuticals Inc., Tensha Therapeutics Inc....
BioCentury | Jun 30, 2016
Strategy

Open house at NIBR

...He also co-founded Acetylon Pharmaceuticals Inc. , C4 Therapeutics Inc. , Syros Pharmaceuticals Inc. , Tensha Therapeutics Inc....
BioCentury | Jan 18, 2016
Company News

Tensha Therapeutics, Roche deal

...acquisition is expected to close this quarter. The companies declined to provide further financial terms. Tensha Therapeutics Inc....
BioCentury | Jan 12, 2016
Company News

Roche BETs on Tensha

...Roche (SIX:ROG; OTCQX:RHHBY) will acquire Tensha Therapeutics Inc. (Cambridge, Mass.) for $115 million in cash up front. Tensha...
BioCentury | Jan 5, 2015
Product Development

BETting early

...2013, the pharma said it expects to report data in late 2014 or early 2015. Tensha Therapeutics Inc....
...Md. Oncoethix S.A., Lausanne, Switzerland Resverlogix Corp. (TSX:RVX), Calgary, Alberta Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Tensha Therapeutics Inc....
BioCentury | Oct 30, 2014
Cover Story

Redistributing BRD4 in inflammation

...investigator in the Department of Medical Oncology at the Dana-Farber Cancer Institute and founder of Tensha Therapeutics Inc....
...Boston, Mass. Resverlogix Corp. (TSX:RVX), Calgary, Alberta, Canada Syros Pharmaceuticals Inc. , Watertown, Mass. Tensha Therapeutics Inc....
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Various

...of BRD4 and other BET bromodomain proteins, has completed Phase II trials to treat atherosclerosis. Tensha Therapeutics Inc....
...Patent application covering JQ1 and related analogs filed by the Dana-Farber Cancer Institute; licensed to Tensha Therapeutics...
BioCentury | Jul 31, 2014
Targets & Mechanisms

Taking a BET on hedgehog

...has filed a patent application covering JQ1 and related analogs. The technology is licensed to Tensha Therapeutics Inc....
...Arbor, Mich. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Stanford University School Of Medicine , Stanford, Calif. Tensha Therapeutics Inc....
BioCentury | Jul 24, 2014
Distillery Therapeutics

Indication: Cancer

...companies have BET bromodomain inhibitors in Phase I testing or preclinical development for various cancers. Tensha Therapeutics Inc....
...2014 Patent application covering JQ1 and related analogs filed by Dana-Farber Cancer Institute; licensed to Tensha Therapeutics...
BioCentury | May 15, 2014
Cover Story

Chromatin's rising tide

...the clinic ( see Table 1). These include TEN-010 , a compound being developed by Tensha Therapeutics Inc....
...NYSE:SNY), Paris, France Structural Genomics Consortium , Oxford, U.K. Syros Pharmaceuticals Inc. , Watertown, Mass. Tensha Therapeutics Inc....
...Oncoethix S.A.; Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) OTX015 BET bromodomain inhibitor Hematologic malignancies Phase I Tensha Therapeutics Inc....
Items per page:
1 - 10 of 33